Head-To-Head Comparison: Precipio (NASDAQ:PRPO) and MDxHealth (NASDAQ:MDXH)

MDxHealth (NASDAQ:MDXH) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current recommendations and price targets for MDxHealth and Precipio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1	0	4	0	2.60
Precipio	1	0	0	0	1.00

MDxHealth presently has a consensus target price of $7.75, suggesting a potential upside of 137.73%. Given MDxHealth’s stronger consensus rating and higher probable upside, equities analysts plainly believe MDxHealth is more favorable than Precipio.

Profitability

This table compares MDxHealth and Precipio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-30.50%	-1,078.01%	-20.05%
Precipio	-5.50%	-10.07%	-6.71%

Insider & Institutional Ownership

10.4% of Precipio shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 16.9% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares MDxHealth and Precipio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$90.05 million	1.71	-$38.07 million	($0.64)	-5.09
Precipio	$22.80 million	1.92	-$4.29 million	($0.82)	-30.40

Precipio has lower revenue, but higher earnings than MDxHealth. Precipio is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MDxHealth has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Precipio

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.